OBiO Technology Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
715
- Stock Symbol
-
688238
- Investments
-
1
- Share Price
-
$1.09
- (As of Friday Closing)
OBiO Technology General Information
Description
Shanghai Obio Technology (Group) Corp Ltd provides contract research organization (CRO) services, including gene therapy vector development and gene function research for basic research, as well as contract development and manufacturing organization (CDMO) services, including IND-enabling CMC research and GMP production of clinical samples for gene therapy drug development.
Contact Information
Website
www.obiosh.comCorporate Office
- Building 19, Lane 908, Ziping Road
- International Medical Park, Pudong New District
- Shanghai, 201321
- China
Corporate Office
- Building 19, Lane 908, Ziping Road
- International Medical Park, Pudong New District
- Shanghai, 201321
- China
OBiO Technology Stock Performance
As of 13-Nov-2026, OBiO Technology’s stock price is $1.09. Its current market cap is $706M with 649M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.09 | $1.03 | $0.74 - $1.39 | $706M | 649M | 32.9M | -$0.05 |
OBiO Technology Financials Summary
As of 30-Sep-2026, OBiO Technology has a trailing 12-month revenue of $42.6M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 895,096 | 631,698 | 410,708 | 736,364 |
| Revenue | 42,633 | 37,225 | 34,583 | 28,948 |
| EBITDA | (30,870) | (18,061) | (31,662) | (19,441) |
| Net Income | (31,781) | (32,687) | (44,849) | (18,083) |
| Total Assets | 348,287 | 298,968 | 312,974 | 367,279 |
| Total Debt | 121,975 | 60,091 | 29,511 | 26,963 |
OBiO Technology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OBiO Technology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
OBiO Technology Comparisons
Industry
Financing
Details
OBiO Technology Competitors (6)
One of OBiO Technology’s 6 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| Creative Biolabs | Corporation | Shirley, NY | ||||
| Virovek | Corporation | Hayward, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
OBiO Technology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
OBiO Technology Patents
OBiO Technology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023103661-A1 | Adeno-associated virus mutant suitable for specific infection of u251 cells | Inactive | 10-Dec-2021 | ||
| WO-2023103662-A1 | Adeno-associated virus mutant suitable for specific infection of u87-mg cells | Inactive | 10-Dec-2021 | ||
| WO-2023071695-A1 | Cuo mutant and use thereof | Inactive | 29-Oct-2021 | ||
| US-20250277233-A1 | Exogenous gene controllable expression virus packaging vector and packaging method | Pending | 07-Dec-2020 | ||
| WO-2022121855-A1 | Exogenous gene controllable expression virus packaging vector and packaging method | Inactive | 07-Dec-2020 | C12N15/86 |
OBiO Technology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
OBiO Technology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OBiO Technology Investments (1)
OBiO Technology’s most recent deal was a Secondary Transaction - Private with ImmVira for . The deal was made on 09-Jan-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ImmVira | 09-Jan-2024 | Secondary Transaction - Private | Drug Discovery |
OBiO Technology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
OBiO Technology FAQs
-
When was OBiO Technology founded?
OBiO Technology was founded in 2013.
-
Where is OBiO Technology headquartered?
OBiO Technology is headquartered in Shanghai, China.
-
What is the size of OBiO Technology?
OBiO Technology has 715 total employees.
-
What industry is OBiO Technology in?
OBiO Technology’s primary industry is BPO/Outsource Services.
-
Is OBiO Technology a private or public company?
OBiO Technology is a Public company.
-
What is OBiO Technology’s stock symbol?
The ticker symbol for OBiO Technology is 688238.
-
What is the current stock price of OBiO Technology?
As of 13-Nov-2026 the stock price of OBiO Technology is $1.09.
-
What is the current market cap of OBiO Technology?
The current market capitalization of OBiO Technology is $706M.
-
What is OBiO Technology’s current revenue?
The trailing twelve month revenue for OBiO Technology is $42.6M.
-
Who are OBiO Technology’s competitors?
Alphamab Oncology, BeOne Medicines, Creative Biolabs, Virovek, and CytomX Therapeutics are some of the 6 competitors of OBiO Technology.
-
What is OBiO Technology’s annual earnings per share (EPS)?
OBiO Technology’s EPS for 12 months was -$0.05.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
